AMDA vs. MOTS, SINT, BJDX, ALLR, OBSV, AMPE, SXTC, APVO, ADTX, and BTTX
Should you be buying Amedica stock or one of its competitors? The main competitors of Amedica include Motus GI (MOTS), Sintx Technologies (SINT), Bluejay Diagnostics (BJDX), Allarity Therapeutics (ALLR), ObsEva (OBSV), Ampio Pharmaceuticals (AMPE), China SXT Pharmaceuticals (SXTC), Aptevo Therapeutics (APVO), Aditxt (ADTX), and Better Therapeutics (BTTX). These companies are all part of the "medical" sector.
Amedica (NASDAQ:AMDA) and Motus GI (NASDAQ:MOTS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.
3.7% of Amedica shares are owned by institutional investors. Comparatively, 20.1% of Motus GI shares are owned by institutional investors. 0.9% of Amedica shares are owned by insiders. Comparatively, 1.6% of Motus GI shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Motus GI had 1 more articles in the media than Amedica. MarketBeat recorded 1 mentions for Motus GI and 0 mentions for Amedica. Amedica's average media sentiment score of 0.00 beat Motus GI's score of -1.00 indicating that Amedica is being referred to more favorably in the media.
Motus GI has a consensus target price of $28.88, suggesting a potential upside of 35,548.15%. Given Motus GI's higher probable upside, analysts clearly believe Motus GI is more favorable than Amedica.
Amedica has a net margin of -139.62% compared to Motus GI's net margin of -4,033.54%. Motus GI's return on equity of 0.00% beat Amedica's return on equity.
Amedica has a beta of -1.24, meaning that its share price is 224% less volatile than the S&P 500. Comparatively, Motus GI has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.
Amedica has higher revenue and earnings than Motus GI. Amedica is trading at a lower price-to-earnings ratio than Motus GI, indicating that it is currently the more affordable of the two stocks.
Amedica received 144 more outperform votes than Motus GI when rated by MarketBeat users. However, 65.73% of users gave Motus GI an outperform vote while only 64.90% of users gave Amedica an outperform vote.
Summary
Motus GI beats Amedica on 10 of the 17 factors compared between the two stocks.
Get Amedica News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
